SCHEMBL4884927

SCHEMBL4884927

C#Cc1ccc(NC(=O)c2nccnc2C(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.54
ALOX15 P16050 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
ALDH1A1 P00352 3/20 0.54
MAPT P10636 2/20 0.54
KMT2A Q03164 2/20 0.53
TSHR P16473 1/20 0.50
ATR Q13535 1/20 0.48
ATM Q13315 1/20 0.47
PRKCI P41743 2/20 0.47
GAA P10253 1/20 0.44
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
PKM P14618 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RET P07949 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4710352 0.85 KDM4E (0.54) KDM4EALOX15L3MBTL1ALDH1A1MAPT
SCHEMBL4709744 0.82 PRKCI (0.43) KDM4EALOX15L3MBTL1ALDH1A1MAPT
SCHEMBL11887634 0.80 KDM4E (0.58) KDM4EALOX15L3MBTL1ALDH1A1MAPT
SCHEMBL5291484 0.80 KDM4E (0.58) KDM4EALOX15L3MBTL1ALDH1A1MAPT
SCHEMBL19392276 0.77 KDM4E (0.56) KDM4EALOX15L3MBTL1ALDH1A1MAPT
SCHEMBL3915690 0.76 MAPT (0.66) KDM4EALOX15L3MBTL1ALDH1A1MAPT
SCHEMBL12793752 0.75 KDM4E (0.56) KDM4EALOX15L3MBTL1ALDH1A1MAPT
SCHEMBL28348601 0.75 P4HTM (0.58) KDM4EALOX15L3MBTL1ALDH1A1MAPT
SCHEMBL8256205 0.74 RET (0.40) ALDH1A1MAPTATRATMPRKCI
SCHEMBL4312329 0.73 NPC1 (0.57) KDM4EALOX15L3MBTL1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed
US-20060287315-A1 Pyrazinedicarboxamides and their use BAYER HEALTHCARE AG (DE) 2006-12-21 US disclosed
WO-2006061116-A1 PYRAZINE DICARBOXAMIDES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2006-06-15 WO disclosed
WO-2006058630-A1 CYCLIC IMINOCARBAMATES AND USE THEREOF BAYER HEALTHCARE AG (DE) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287315-A1 Pyrazinedicarboxamides and their use PEPD, AADAC, PYCARD KDM4E 1426/4885ALOX15 1615/4885L3MBTL1 4687/4885
US-20080214533-A1 Cyclic Iminocarbamates And Their Use F2, UQCRB, F12 KDM4E 3856/4885ALOX15 880/4885L3MBTL1 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.